검색어: chelator (영어 - 몰타어)

chelator
aġent kelanti

- if you are currently taking another iron chelator medication.
- jekk bħal issa qed tieħu xi mediċina oħra li hija kelatur tal- ħadid.

the active substance in ferriprox, deferiprone, is an iron chelator.
is-sustanza attiva f’ferriprox, deferiprone, hija kelatur tal-ħadid.

the active substance in exjade, deferasirox, is an ‘ iron chelator’.
is- sustanza attiva f' exjade, deferasirox, hija 'kelatur tal- ħadid' (iron chelator).

deferasirox is an orally active chelator that is highly selective for iron (iii).
deferasirox huwa kelatur attiv meta jittieħed mill-ħalq li huwa selettiv ħafna għall-ħadid (iii).

if you have moderate or severe kidney disease. if you are currently taking any other iron chelator medicines.
jekk tbati minn mard ħafif jew akut tal-kliewi. jekk bħal issa qed tieħu kwalunkwe mediċina oħra li hija kelatur tal-ħadid.

this is probably due to some extent of complexion of zinc by the chelator, thus reducing the effect of both active substances.
dan probabilment huwa minħabba xi ammont ta 'rabta ta' ta 'zinc mal- kelaturi, li b’ hekk inaqqas l- effett taż- żewġ sustanzi attivi.

therefore, it must not be combined with other iron chelator therapies (see section 4.3).
għaldaqstant, m’għandux jingħata flimkien ma’ terapiji oħra ta’ kelaturi tal-ħadid (ara sezzjoni 4.3).

it is an iron chelator which is a medicine used to remove the excess iron from the body (also called iron overload).
huwa kelatur tal-ħadid li hija mediċina li tintuża biex tneħħi l-ħadid żejjed mill-ġisem (kundizzjoni magħrufa bħala tagħbija żejda tal-ħadid).

combination with other iron chelator therapies as the safety of such combinations has not been established (see section 4.5).
użu ma’ terapiji ta’ kelaturi tal-ħadid oħrajn għax is-sigurtà ta’ dawn il-kombinazzjonijiet ma ġietx stabilita (ara sezzjoni 4.5).

however, a post-exposure interval > 1 hour does not preclude the administration and effective action of chelator, even if with reduced efficiency.
madankollu, intervall > siegħa wara l-espożizzjoni ma jipprekludix l-għoti u l-azzjoni effettiva ta’ kelatur, anki jekk b’effiċjenza mnaqqsa.

however, a post-exposure interval > 1 hour does not preclude the administration and effective action of chelator with reduced efficiency.intravenous administration should not be protracted over more than 2 hours.
madankollu, intervall ta' wara l-esponiment ta' > minn siegħa ma jeskludix l-għoti u l-azzjoni effettiva ta' kelatur b'nuqqas ta' effiċjenza.

however, in patients with liver iron concentration < 7 mg fe/ g dw treated with exjade (5 and 10 mg/ kg) or deferoxamine (20 to 35 mg/ kg), non-inferiority was not established due to imbalance in the dosing of the two chelators.
madankollu, f’ pazjenti li kellhom konċentrazzjoni tal- ħadid fil- fwied < 7mg fe/ g dw kurati b’ exjade (5 u 10 mg/ kg) jew deferoxamine (20 sa 35 mg/ kg), ma ġiex stabbilit jekk ma kienx 31 inferjuri minħabba żbilanċ fid- dużaġġi taż- żewġ kelaturi.